Related Experiment Videos
Aromatase and aromatase inhibitors
1Tokyo Metropolitan Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113, Japan. maktoi77@wa2.so-net.ne.jp
Breast Cancer (Tokyo, Japan)
|January 16, 2002
Summary
Aromatase inhibitors effectively reduce estrogen synthesis in postmenopausal breast cancer patients. These inhibitors show efficacy comparable to or better than tamoxifen in metastatic and neoadjuvant settings.
Area of Science:
- Oncology
- Endocrinology
Background:
- Aromatase inhibition offers both local and systemic treatment for breast cancer.
- Third-generation aromatase inhibitors potently suppress intratumoral estrogen synthesis, especially in postmenopausal women.
Purpose of the Study:
- To review the efficacy of aromatase inhibitors in various breast cancer treatment settings.
- To explore the potential of aromatase inhibitors in neoadjuvant therapy.
Main Methods:
- Review of accumulated data on aromatase inhibitor efficacy.
- Analysis of clinical trial results in first-line, second-line, adjuvant, and neoadjuvant settings.
Main Results:
- Aromatase inhibitors demonstrate antitumor activity equal to or superior to tamoxifen in metastatic breast cancer.
- Preliminary studies show high response rates for aromatase inhibitors in the neoadjuvant setting.
Conclusions:
- Aromatase inhibitors are effective in treating metastatic breast cancer and show promise in neoadjuvant therapy.
- Neoadjuvant aromatase inhibitor therapy may become a standard for hormone-responsive, postmenopausal breast cancer.